Keith Lane was named Executive Vice President, Head of Kiora Pharmaceuticals Inc. As of November 6, 2026, Kiora Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to September 8, 2026, naming 1 appointment (Form 8-K, September 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kiora Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kiora Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-09-08. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Kiora Pharmaceuticals Inc files it.
Also on the record for Kiora Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 17, 2026 | Stake report, Schedule 13G, by Baselake Partners, LP | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Alyeska Investment Group, L.P. | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 3.388% of the class | 5%+ stakes | Source |
| April 21, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13G/A, by Orin Hirschman | 4.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 5.299% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kiora Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Kiora Pharmaceuticals Inc and the records around it.
Kiora Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Sep 2026
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Watch Kiora Pharmaceuticals Inc
Get an email when Kiora Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kiora Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kiora Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiora Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-08 | In | Executive Vice President, Head | 8-K, 2026-09-08 | ||
| 2026-04-02 | Reported | not named in the filing | 8-K, 2026-04-02 |
Who leads Kiora Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Executive Vice President, Head: Keith Lane, appointed (filed 2026-09-08).
New leaders reset buying decisions — get the Full Report on Kiora Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Kiora Pharmaceuticals Inc (free up to 3)
Find people with the same kind of experience as the Executive Vice President, Head at Kiora Pharmaceuticals Inc, with the record behind each one.
Find candidates like Head at Kiora Pharmaceuticals IncEvery change, in the filing's words
Appointed: Keith Lane, Executive Vice President, Head
On September 8, 2026 (the "Effective Date"), Kiora Pharmaceuticals Inc. (the "Company") appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs of the Company, effective as of the Effective Date.
- Mr. Lane, age 45, previously served as Chief Scientific Officer ("CSO") for Ora, Inc. ("Ora"), an ophthalmology-focused clinical research organization, from September 2025 to July 2026.
- Prior to his CSO role, while still at Ora, he served as Senior Vice President and Therapeutic Area Head-Posterior Segment from October 2019 to September 2025, as well as various other roles since joining their company in August 2003.
- During his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission.
- His experience spans small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.
- In connection with Mr. Lane's appointment as Executive Vice President, Head of Clinical Development and Regulatory Affairs, the Company entered into an Offer Letter (the "Offer Letter") with Mr. Lane on June 22, 2026 and effective as of the Effective Date.
- Pursuant to the Offer Letter, Mr. Lane will receive an annual base salary of $350,000, a sign-on bonus of $75,000, and he is entitled to receive a performance bonus with a target of up to 35% of his annual base salary for the applicable fiscal year.
Reported
On April 1, 2026, Eric J. Daniels, M.D., MBA, the Chief Development Officer of Kiora Pharmaceuticals, Inc. (the "Company"), notified the Company that he will resign as Chief Development Officer effective as of April 17, 2026 (the "Effective Date") to pursue another opportunity.
- Mr. Daniel's resignation did not result from any disagreement regarding the Company's operations, policies or practices.
Kiora Pharmaceuticals Inc's funding history
Tools for this story
Each opens in a new tab, filled in for Kiora Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.